What Micrima does

Micrima Limited is a Bristol, UK-based medical technology company, founded in 2005, that has developed Mi~Scan, a CE-marked Class IIa handheld medical device that uses low-energy radio-frequency signals to measure breast tissue density without ionizing radiation or breast compression. A trained practitioner performs the scan in an approximate 10-minute in-person appointment, producing BI-RADS density categories and percentage density values for each breast; the device is validated for breast tissue thickness of 20-196 mm and is positioned as complementary to mammography, particularly for younger women and women with dense breast tissue where standard mammograms may be less informative. The company operates under EU MDR 2017/745 (Notified Body IMQ 0051) and holds ISO 13485 quality management certification from BSI. Its underlying technology is protected by nine granted patents.

The product portfolio combines hardware measurement with a regulated software stack. Mi~Score is an optional add-on service that integrates Mi~Scan density data with structured clinical inputs and applies Tyrer-Cuzick and BOADICEA breast cancer risk models — both recognized in NHS/NICE familial-risk pathways — to generate personalized risk estimates, visual density maps, and longitudinal trend tracking. Outputs are delivered through Mi~Scan+, a CE-marked Class I software medical device accessed via web portal. Pivotal clinical validation was conducted with Leeds Teaching Hospitals NHS Trust (approximately 1,000 women), and community acceptability was assessed in a study sponsored by NHS Greater Manchester Cancer Alliance.

Micrima operates a direct-to-consumer service model. Customers request information via the website, receive personal outreach from the Partnerships & Growth Manager (Imogen), and book in-person appointments at Micrima HQ (Two Glass Wharf, Bristol) or selected partner locations around the UK. Pricing is quote-based and not publicly disclosed; payment is accepted via Visa, Mastercard, American Express, Apple Pay, PayPal, and Klarna. Revenue derives from per-appointment Mi~Scan scans and optional Mi~Score professional-services reports. The customer base consists of individual consumers — general-population women, women with family history of breast cancer, and women with dense breasts — rather than enterprise B2B contracts. Total disclosed funding across eight rounds from 2006 through April 2021 is approximately $23.3M, with investors including Technology Venture Partners, ACF Investors, Nesta Ventures, Swarraton Partners, YFM Equity Partners, Parkwalk Advisors, Renaissance Capital Partners, VentureFounders, the University of Bristol Enterprise Fund, Quester Capital, and Sulis Innovation. No operating geographies beyond the United Kingdom are disclosed.

Name

Micrima

Legal name

Micrima Limited

Website

https://micrima.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Micrima Limited is a UK medical device company that operates the CE-marked Mi~Scan handheld radio-frequency breast density measurement service, serving adult women seeking radiation-free, compression-free breast density information and personalized cancer risk profiling via direct-to-consumer in-person appointments.

Ownership category

akta.pro rank

Product category

Breast Imaging Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Diagnostic Imaging Centers (621512)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industry

Women’s Imaging & Breast Health Centers (HLAFAJAJ)

Keywords

• Breast density measurement
• Radiation-free imaging
• Radio-frequency diagnostics
• Breast cancer screening
• Women's health imaging

Headquarters

HQ city

Bristol

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D

Revenue model

1. Mi~Scan Appointment Service: In-person scan service where trained practitioners perform breast density measurements using the Mi~Scan handheld device. Customers book appointments through the website booking system and pay for the service at point of sale. Payment accepted via Visa, Mastercard, American Express, Apple Pay, PayPal, and Klarna.
2. Mi~Score Optional Add-on Report: Optional supplemental service that builds on Mi~Scan measurements, providing density maps, personalized breast cancer risk estimates using validated clinical models (Tyrer-Cuzick, BOADICEA), and longitudinal tracking. Delivered through Mi~Scan+ web portal (Class I software medical device).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Micrima sells in-person breast density measurement appointments through its proprietary Mi~Scan® handheld device, which uses low-energy radio-frequency signals (no radiation, no compression) to give women personal breast-density information. The optional Mi~Score® add-on layers Tyrer-Cuzick and BOADICEA-validated personalised breast cancer risk profiling, density maps and longitudinal tracking delivered via the Mi~Scan®+ Class I software web portal.

Product overview

Micrima offers a unified breast health monitoring system built around the Mi~Scan® handheld radio-frequency device for measuring breast density. This core device connects to the Mi~Scan®+ Web Portal, a regulated Class I software medical device that processes measurements into the optional Mi~Score® service — providing visual density maps and personalised breast cancer risk estimates using established clinical risk models. The architecture combines hardware measurement with cloud-based software analysis for comprehensive breast density assessment.

Differentiator

Problem solved

Functional benefit

Brands

• Mi~Scan®: Radiation-free breast density measurement device using radio-frequency technology. CE-marked Class IIa medical device that measures breast tissue properties to provide personal breast-density information.
• Mi~Score®
• Mi~Scan®+

Products and services

• Mi~Scan® breast density scan service An in-person appointment in which a trained practitioner uses the handheld Mi~Scan® device to take a series of gentle radio-frequency measurements of the breast, providing personal breast-density information (BI-RADS category and percentage density for each breast) in approximately 10 minutes, with no radiation and no compression. Targeted at adult women seeking personal breast-density information, including those with dense breasts and family history of breast cancer.
• Mi~Score® personal breast cancer risk profiling An optional add-on service that combines Mi~Scan® breast-density data with personal/family history, lifestyle and genetic profile inputs and applies Tyrer-Cuzick and BOADICEA validated risk models to generate personalised breast cancer risk estimates, visual density maps and trend tracking over time. Delivered to the customer through the Mi~Scan®+ Web Portal.
• Mi~Scan®+ Web Portal (Class I software medical device) A regulated Class I software medical device web portal that delivers Mi~Score® outputs to customers, including breast cancer statistical risk prediction percentages, graphical visualisation of estimated fibroglandular tissue distribution, percentage-based density measurements and longitudinal density history.

Quantifiable outcome

• ~1,000 women participated in pivotal clinical investigation at Leeds Teaching Hospitals NHS Trust
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Leeds Teaching Hospitals NHS TrustcoreStrategic or Co-development PartnerClinical validation partner for pivotal investigation of Mi~Scan technology. Approximately 1,000 women participated in clinical study validating the device's safety and performance. Mi~Scan is clinically validated with Leeds Teaching Hospitals NHS Trust.
• NHS Greater Manchester Cancer AlliancecoreStrategic or Co-development PartnerSponsored community acceptability study assessing Mi~Scan use in everyday settings. Demonstrated exceptionally high acceptance rates among participants. Study supports use in community-based settings.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Volpara Health: Volpara builds software that quantifies breast density from mammograms and provides personalised breast cancer risk scoring. It is the closest direct peer to Micrima's Mi~Score offering, both addressing objective breast density and risk assessment, although Volpara is software-only and rides on incumbent mammography hardware.
• iCAD: iCAD offers AI-powered breast health solutions including density assessment and cancer detection, competing with Mi~Score on risk profiling. Both companies target the breast density / risk stratification workflow for clinicians and patients.
• Densitas: Densitas provides AI-based breast density measurement and risk assessment software integrated with mammography workflows. It is an emerging direct competitor in the density-assessment category that Micrima addresses via Mi~Scan/Mi~Score.

Broad incumbents

• Hologic: Hologic is the dominant mammography hardware and breast health incumbent, whose installed base underpins much of the breast-imaging market. While not offering an RF density device, Hologic's breast health portfolio (including its own density-assessment software) is the established alternative Micrima competes against in clinical settings.
• GE HealthCare: GE HealthCare provides mammography systems and broader breast imaging solutions to hospitals and screening programmes worldwide. As a major imaging incumbent, it sets the clinical workflow standard that novel entrants like Micrima must integrate with or differentiate from.
• Siemens Healthineers: Siemens Healthineers offers mammography and breast imaging equipment, including AI-enabled density and risk assessment tools. It is a broad incumbent competitor in the breast imaging category where Micrima is positioning a complementary RF-based density service.

Emerging players

• Lunit: Lunit develops AI solutions for cancer detection and tissue characterisation, including breast density and risk assessment. As an emerging AI player, it competes in the same risk-stratification layer as Micrima's Mi~Score, but does so via algorithms layered on mammograms rather than a dedicated RF hardware device.
• ScreenPoint Medical: ScreenPoint Medical provides AI-based breast imaging decision support, including density and cancer detection tools for mammography. It overlaps with Micrima's Mi~Score risk-profiling proposition by addressing personalised breast assessment within existing clinical imaging workflows.

Others

• Therapy Analytics / Myriad Genetics (risk-model providers): Myriad Genetics offers hereditary cancer risk testing (including BRCA1/BRCA2 used in Mi~Score inputs) and is a supplier of genetic data feeding the same breast cancer risk-assessment workflow Micrima commercialises. Relevant as an ecosystem enabler and partial competitor for risk-stratified breast health consumers.
• Prevent Breast Cancer (charity / clinical research partner): UK-based charity funding breast cancer prediction, prevention, and early-detection research. Comparable as a UK stakeholder in the dense-breast awareness and risk-assessment space that Micrima's Mi~Scan / Mi~Score proposition targets, and a potential partnership channel rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/micrimalimited
• LinkedInlinkedin.com/company/micrima-limited

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micrima